Catalyst Pharmaceuticals (NASDAQ:CPRX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Friday. They currently have a $6.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 94.81% from the company’s current price.
The analysts wrote, “Our price target of $6/share is based on an equally weighted composite of: (a) $6.62/ share, as a 35x multiple of taxed and diluted 2024 GAAP EPS of $0.57 discounted back to 2018 at 20%; and (b) an NPV of discounted cash flows between 2018-2024 of $4.46/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of Firdapse to secure regulatory approval in the US; and (2) failure of Firdapse to achieve peak commercial revenue estimates in our model due to market size, penetration rates, and/or pricing.””
A number of other research firms also recently commented on CPRX. Cantor Fitzgerald initiated coverage on Catalyst Pharmaceuticals in a research note on Thursday, September 20th. They issued an “overweight” rating and a $8.00 price target for the company. BidaskClub upgraded Catalyst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 27th. Oppenheimer set a $6.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 9th. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Monday, August 13th. Finally, ValuEngine downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $5.71.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.08). Analysts anticipate that Catalyst Pharmaceuticals will post -0.29 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. MetLife Investment Advisors LLC bought a new position in Catalyst Pharmaceuticals in the second quarter worth about $157,000. Los Angeles Capital Management & Equity Research Inc. lifted its holdings in Catalyst Pharmaceuticals by 152.9% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 42,900 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 25,940 shares during the last quarter. Lido Advisors LLC lifted its holdings in Catalyst Pharmaceuticals by 46.5% in the second quarter. Lido Advisors LLC now owns 87,506 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 27,766 shares during the last quarter. Rhumbline Advisers lifted its holdings in Catalyst Pharmaceuticals by 34.7% in the second quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock worth $283,000 after acquiring an additional 23,383 shares during the last quarter. Finally, California State Teachers Retirement System lifted its holdings in Catalyst Pharmaceuticals by 18.2% in the first quarter. California State Teachers Retirement System now owns 133,262 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 20,484 shares during the last quarter. 51.48% of the stock is currently owned by hedge funds and other institutional investors.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Read More: Why do companies engage in swaps?
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.